Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Barlas

Showing results (81-90 of 149) with videos related to

Pageof 15
Sort By:
P & T : a Peer-Reviewed Journal for Formulary Management|April 13, 2016
Medication Practices at Center Of Hospital and Nursing Home Proposals: Discharge and Pharmacy Requirements to ChangeStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|November 5, 2015
Congress Likely to Rein In 340B Drug Discount Program: The HRSA's Draft Guidance and a Proposed Rule Give Legislators an OpeningStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 5, 2019
HHS Proposes Steps Toward Health Data Interoperability CMS and ONC Proposals Would Implement Cures ActStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 30, 2009
California e-Pedigree Rules Pose Challenges for Pharmacies: Will the FDA Follow in the Golden State's Footsteps?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|September 15, 2009
FDA's Janet Woodcock Riding High: CDER Director Wins "Wows" Amid Agency WoesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|May 9, 2017
Drug Companies Worry About New "Totality of Evidence" Standard: Is It an About-Face From the FDA on Off-Label Promotion?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|October 23, 2014
The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricingStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|December 19, 2018
P&T Committees Get New Leeway to Control Part C and Part D Drug Costs: Door Opens to More Step Therapy And Indication-Based FormulariesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|December 19, 2018
Health Care Price Transparency Initiatives Are All the Rage: But Burgeoning Efforts Suffer from Myriad ShortcomingsStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|July 23, 2014
FDA Draft Guidances Compound the Compounding Uncertainty: A New List of 503B Outsourcing Facilities Offers No Guarantee of AnythingStephen Barlas
Pageof 15

Showing results (81-90 of 149) with videos related to

Sort By:
Pageof 15
P & T : a Peer-Reviewed Journal for Formulary Management|April 13, 2016
Medication Practices at Center Of Hospital and Nursing Home Proposals: Discharge and Pharmacy Requirements to ChangeStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|November 5, 2015
Congress Likely to Rein In 340B Drug Discount Program: The HRSA's Draft Guidance and a Proposed Rule Give Legislators an OpeningStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 5, 2019
HHS Proposes Steps Toward Health Data Interoperability CMS and ONC Proposals Would Implement Cures ActStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|June 30, 2009
California e-Pedigree Rules Pose Challenges for Pharmacies: Will the FDA Follow in the Golden State's Footsteps?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|September 15, 2009
FDA's Janet Woodcock Riding High: CDER Director Wins "Wows" Amid Agency WoesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|May 9, 2017
Drug Companies Worry About New "Totality of Evidence" Standard: Is It an About-Face From the FDA on Off-Label Promotion?Stephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|October 23, 2014
The clinical trial model is up for review: time, expense, and quality of results are at issue, as is the relationship to drug pricingStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|December 19, 2018
P&T Committees Get New Leeway to Control Part C and Part D Drug Costs: Door Opens to More Step Therapy And Indication-Based FormulariesStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|December 19, 2018
Health Care Price Transparency Initiatives Are All the Rage: But Burgeoning Efforts Suffer from Myriad ShortcomingsStephen Barlas
P & T : a Peer-Reviewed Journal for Formulary Management|July 23, 2014
FDA Draft Guidances Compound the Compounding Uncertainty: A New List of 503B Outsourcing Facilities Offers No Guarantee of AnythingStephen Barlas
Pageof 15